Alexiades 2018 is the strongest single piece of evidence for RF microneedling and cellulite.
Fifty people with moderate cellulite — grade II to III on the standard grading scale — on the back and outer surface of the thigh (the posterolateral thigh) received one treatment. RF was delivered into the subcutaneous layer at a controlled 67°C for four seconds. Patients were followed at one, three and six months.
Photographs were graded by three dermatologists who were blinded, and success required at least two of the three to agree. Success was defined the way the FDA defines it for cellulite work: at least a one-point improvement in either the number of dimples or the severity of the undulations.
93% of patients met that bar at six months. Average pain during treatment was 3.74 out of 10. No adverse events were reported. Three quarters of patients said they were satisfied at six months.
A companion trial from the same group in 2021 treated 62 areas across 31 women — upper arms, above the knee, and the bra line — again with a single treatment. Improvement was reported at 100% of timepoints for arms and bra line, but was much weaker above the knee. Transient side effects were common: redness in 69%, swelling in 46%, mild bruising in 32%, all resolving within about five days.
It is a subcutaneous protocol, not the facial one. This is the caveat most likely to mislead someone who has read about Morpheus8 for the face. The cellulite work puts RF energy into the fat layer, deliberately, rather than into the dermis. Facial RF microneedling works at dermal depth to remodel collagen. A clinic offering "Morpheus8 for cellulite" is offering something technically different from the facial treatment, and you should ask what depth and protocol they are using.
One group, with manufacturer ties. Dr Alexiades is a prolific author on this class of device and has relationships with manufacturers. Both cellulite and body-laxity trials come from the same investigator group. That is not evidence of anything being wrong, but independent replication is what turns a promising trial into an established one, and it has not happened. A 2021 critical review of 42 higher-quality RF microneedling studies counted exactly one higher-quality cellulite study.
No untreated control. Nobody in the trial went untreated for comparison. Blinded photographic grading helps a lot, but it does not substitute for a control group.
There is one other Morpheus8-specific item: a 2022 case series looking at the Morpheus8 applicator for cellulite. Its sample size is not stated in the PubMed record, so nothing quantitative can be drawn from it.
This one is worth getting precisely right, because clinic copy routinely gets it wrong.
Morpheus8 is not cleared for cellulite. Its clearances are for electrocoagulation and haemostasis (K192695, December 2019) and, from 2023, use "where coagulation/contraction of soft tissue or hemostasis is needed". No cosmetic use is named anywhere in that wording.
InMode does hold a real cellulite clearance — but on different devices. The wording "temporary reduction in the appearance of cellulite" belongs to the BodyFX, WMbody and EmBodyFX applicators, which deliver RF combined with massage. That clearance dates back to K131362 in 2013 and carries through to the Evolve Trim applicator.
And InMode's fat-reduction clearance is different again. "Non-invasive lipolysis of the abdomen" and "reduction in circumference of the abdomen" are on-label — but only for the Evolve Transform applicator, and only for the abdomen. Not the arms, thighs, flanks or chin. And not Morpheus8.
So "Morpheus8 is FDA cleared for cellulite" is not accurate. Using Morpheus8 for cellulite is off-label — legal and routine, but not regulator-reviewed for that purpose. And a clearance would not have meant proof of benefit anyway; it means the device is similar enough to an earlier one.
Almost no published RF microneedling trial used Morpheus8. The Alexiades cellulite work used a temperature-controlled subcutaneous microneedle RF system, and the wider literature comes from Lutronic, Jeisys, Pollogen, Lumenis and unnamed devices.
A PubMed search for Morpheus8 returns 16 records, several of them in industry-sponsored journal supplements, and no randomised controlled trial of the device was found. If you are being shown research for a Morpheus8 cellulite treatment, it is worth asking which device the study actually used.
Six months is the evidence horizon. The cellulite trial measured to six months, and so does essentially every controlled study in this field. Clinic claims of one to three years have no published source.
RF microneedling also does not stop the process that produced the cellulite in the first place, and no study has separated ongoing change from treatment effect.